"In 2009, we reacted swiftly and appropriately in the face some of our industry's most difficult challenges. As a result, we have maintained our market position," Camp said. "We also generated a significant increase in operating cash flow, which has enabled us to return $58.1 million directly to shareholders in the form of increased dividends and share repurchases."

Guidance for Fiscal Year 2010

Guidance for fiscal year 2010 reflects a broader range than Hillenbrand normally gives investors, primarily because a number of uncertainties make it more difficult to predict results. While the economy has shown signs of recovery, the company believes it could be more prolonged than past recessions. In addition, there are many conflicting reports about the potential severity of this year's influenza and pneumonia season, with both normal seasonal and H1N1 flu strains in circulation.

Hillenbrand expects 2010 revenues will be from 3 percent below to 3.1 percent above FY09 revenues, ranging from $630 million to $670 million. Earnings per diluted share will range from $1.40 to $1.67, with net income projected to be between $86 million and $103 million. Excluding approximately $3 million to $5 million in estimated legal costs related to ongoing antitrust litigation, we expect fiscal 2010 earnings per diluted share to range from $1.45 to $1.70. Guidance for 2010 includes modest investments in growth initiatives in the death care industry, although it does not include any impact from future mergers or acquisitions, or the impact of changes in limited partnership investments.

"Although we have traditionally been less susceptible to economic downturns than most industries, the level of uncertainty among consumers remains reasonably high," Camp said. "That makes it more challenging for us to forecast results for the coming fiscal year. We can, however, say with certainty that Hillenbrand's employees are continuing to provide our customers and the families they serve with the innovation, quality and service they expect, which will in turn continue to drive value for our shareholders."

SOURCE Hillenbrand, Inc.

Tag Cloud

Accutane kaufen Ohne Rezept
Aciphex kaufen Ohne Rezept
Actos kaufen Ohne Rezept
Aldactone kaufen Ohne Rezept
Allegra kaufen Ohne Rezept
Amoxicillin kaufen Ohne Rezept
Antabuse kaufen Ohne Rezept
Arcoxia kaufen Ohne Rezept
Atrovent kaufen Ohne Rezept
Bactrim kaufen Ohne Rezept
Benicar kaufen Ohne Rezept
Biaxin kaufen Ohne Rezept
Buspar kaufen Ohne Rezept
Cardura kaufen Ohne Rezept
Cipro kaufen Ohne Rezept
Cleocin kaufen Ohne Rezept
Clonidine kaufen Ohne Rezept
Coreg kaufen Ohne Rezept
Crestor kaufen Ohne Rezept
Differin kaufen Ohne Rezept
Effexor kaufen Ohne Rezept
Elavil kaufen Ohne Rezept
Erythromycin kaufen Ohne Rezept
Evista kaufen Ohne Rezept
Femara kaufen Ohne Rezept
Flagyl kaufen Ohne Rezept
Fosamax kaufen Ohne Rezept
Glucophage kaufen Ohne Rezept
Hydrochlorothiazide kaufen Ohne Rezept
Imitrex kaufen Ohne Rezept
Inderal kaufen Ohne Rezept
Lamisil kaufen Ohne Rezept
Lasix kaufen Ohne Rezept
Levaquin kaufen Ohne Rezept
Lotensin kaufen Ohne Rezept
Maxalt kaufen Ohne Rezept
Micardis kaufen Ohne Rezept
Misoprostol kaufen Ohne Rezept
Naltrexone kaufen Ohne Rezept
Nexium kaufen Ohne Rezept
Nolvadex kaufen Ohne Rezept
Norvasc kaufen Ohne Rezept
Ortho Tri-Cyclen kaufen Ohne Rezept
Parlodel kaufen Ohne Rezept
Plavix kaufen Ohne Rezept
Premarin kaufen Ohne Rezept
Priligy kaufen Ohne Rezept
Propecia kaufen Ohne Rezept
Retin-A kaufen Ohne Rezept
Robaxin kaufen Ohne Rezept
Skelaxin kaufen Ohne Rezept
Suprax kaufen Ohne Rezept
Synthroid kaufen Ohne Rezept
Trileptal kaufen Ohne Rezept
Valtrex kaufen Ohne Rezept
Ventolin kaufen Ohne Rezept
Xenical kaufen Ohne Rezept
Yasmin kaufen Ohne Rezept
Zithromax kaufen Ohne Rezept
Zocor kaufen Ohne Rezept
Zyban kaufen Ohne Rezept
Zyvox kaufen Ohne Rezept